Ocugen, Inc. (OCGN): Nasdaq/NYSE listing notice — Ocugen receives Nasdaq extension to Dec 29, 2025 to meet $1 bid price requirement

Ocugen, Inc.

Ocugen granted 180-day extension until Dec 29, 2025 to regain compliance with Nasdaq minimum bid price $1.00.
Previously, on Dec 31, 2024, Nasdaq warned that stock had traded below $1 for 30 consecutive business days.
If bid price closes at $1.00 or more for 10 consecutive business days before Dec 29, compliance will be achieved.
Failure to demonstrate compliance by Dec 29 may result in delisting, subject to possible appeal to Nasdaq Hearing Panel.
No assurance that appeal would succeed if delisting is determined.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Ocugen, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

July 1, 2025, Ocugen, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) that the Company has been granted an additional 180 calendar days, or until December 29, 2025, to regain compliance with the minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) as required by Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously reported, on December 31, 2024, Nasdaq notified the Company that for the last 30 consecutive business

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-064695

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.